- Home
- AIRI vs INAB Comparison
AIRI vs INAB Comparison
Compare AIRI & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRI
- INAB
- Stock Information
- Founded
- AIRI 1979
- INAB 2016
- Country
- AIRI United States
- INAB United States
- Employees
- AIRI N/A
- INAB N/A
- Industry
- AIRI Military/Government/Technical
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- AIRI Industrials
- INAB Health Care
- Exchange
- AIRI Nasdaq
- INAB Nasdaq
- Market Cap
- AIRI 13.4M
- INAB 14.5M
- IPO Year
- AIRI N/A
- INAB 2021
- Fundamental
- Price
- AIRI $3.38
- INAB $2.17
- Analyst Decision
- AIRI
- INAB Strong Buy
- Analyst Count
- AIRI 0
- INAB 2
- Target Price
- AIRI N/A
- INAB $108.00
- AVG Volume (30 Days)
- AIRI 38.5K
- INAB 383.7K
- Earning Date
- AIRI 08-13-2025
- INAB 08-07-2025
- Dividend Yield
- AIRI N/A
- INAB N/A
- EPS Growth
- AIRI N/A
- INAB N/A
- EPS
- AIRI N/A
- INAB N/A
- Revenue
- AIRI $53,182,000.00
- INAB N/A
- Revenue This Year
- AIRI $5.59
- INAB N/A
- Revenue Next Year
- AIRI $5.00
- INAB N/A
- P/E Ratio
- AIRI N/A
- INAB N/A
- Revenue Growth
- AIRI 0.29
- INAB N/A
- 52 Week Low
- AIRI $3.00
- INAB $2.06
- 52 Week High
- AIRI $9.44
- INAB $27.60
- Technical
- Relative Strength Index (RSI)
- AIRI 46.11
- INAB 27.49
- Support Level
- AIRI $3.31
- INAB $2.06
- Resistance Level
- AIRI $3.72
- INAB $2.31
- Average True Range (ATR)
- AIRI 0.20
- INAB 0.31
- MACD
- AIRI -0.01
- INAB -0.00
- Stochastic Oscillator
- AIRI 14.63
- INAB 4.74
About AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.